Our Triple A Polyclonals to validate key proteins in pancreatic cancer research
Kisling SG, et al, A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2023 Sep 15;29(18):3759-3770. PMID: 37432996.
A new gene signature to identify patients with pancreatic ductal carcinoma.
In a study published in Clin Cancer Res. Kisling et al, identifies a novel gene signature associated with poor prognosis in pancreatic ductal adenocarcinoma (PDAC) patients.
The studies aimed to find a gene signature that can predict the survival outcomes of patients with PDAC. The authors identified a set of genes, driven by the HOXA10 gene, that were associated with poor survival in PDAC patients.
This gene signature was validated and found to be linked to immune suppression and enhanced tumor growth. The findings suggest that this gene signature could be used to stratify PDAC patients based on their survival outcomes and potentially identify new therapeutic targets.
To help validate the differential proteins expression in PDAC tissues and their association with poor survival, the human tissue slides were incubated using IHC with our Triple A Polyclonals antibodies:
Anti-PDIA4 (HPA006140), Anti-EIF4G1 (HPA028487), and Anti-MRPS10 (HPA029134).
Read the full study